GCTK glucotrack.com Total Debt to Capital

GlucoTrack, Inc. (GCTK) relies on professional management with a global vision, which minimizes administrative risks. The price indicator on the chart demonstrates a total debt-to-equity ratio of 0.00. The business is based on the development of non-invasive glucose sensors in collaboration with specialized centers. However, intensive clinical trials of new developments are triggering a significant liquidity drain and creating a temporary financial deficit.

Developing non-invasive glucose monitoring systems in partnership with medtech centers requires significant R&D capital expenditures. The debt-to-equity ratio reflects the balance between debt financing for these innovations and shareholder equity, demonstrating the degree of financial autonomy of GlucoTrack, Inc. (GCTK) and its resilience to market volatility or rising interest rates during periods of economic instability.